Found 76 matching trials
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer PHASE1 This phase I clinical trial evaluates the safety and feasibility of adminis...
Show More Location
UCLA / Jonsson Comprehensive Cancer Center
Learn More & Join Trial
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma PHASE1 This phase I trial studies the side effects and best dose of genetically mo...
Show More Status
Active Not Recruiting
Location
City of Hope Medical Center
Learn More & Join Trial
O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas PHASE1 This phase I/II trial studies the side effects and best dose of temozolomid...
Show More Location
Fred Hutch/University of Washington Cancer Consortium
Learn More & Join Trial
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia PHASE1 Background:
Sickle cell disease (SCD) is an inherited disorder of the bloo...
Show More Status
Active Not Recruiting
Location
National Institutes of Health Clinical Center
Learn More & Join Trial
Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L PHASE2 The purpose of this study is to compare the effects, good and bad, of two w...
Show More Location
Memoral Sloan Kettering Cancer Center
Learn More & Join Trial
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant PHASE2 Plerixafor, administered at a dose of 240 ug/kg, potentiates the effect of ...
Show More Location
Duke University Medical Center
Learn More & Join Trial
Scleroderma Treatment With Autologous Transplant (STAT) Study PHASE2 This phase II trial studies how well giving cyclophosphamide and anti-thymo...
Show More Location
City of Hope Comprehensive Cancer Center
Learn More & Join Trial
Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy PHASE1 Background:
X-linked severe combined immunodeficiency (XSCID) is a rare in...
Show More Status
Enrolling By Invitation
Location
National Institutes of Health Clinical Center
Learn More & Join Trial
Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients PHASE2 Treatment Study to assess of safety and efficiency of conditioning with Ple...
Show More Location
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
Learn More & Join Trial
A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients PHASE2 Treatment Study to assess of safety and efficiency of conditioning with Ple...
Show More Location
Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and Immunology
Learn More & Join Trial